A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

Most anticancer drugs entering clinical trials fail to achieve approval from the US FDA. Drug development is hampered by the lack of preclinical models with therapeutic predictive value. Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its appl...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sivanand, Sharanya, Peña-Llopis, Samuel, Zhao, Hong, Kucejova, Blanka, Spence, Patrick, Pavia-Jimenez, Andrea, Yamasaki, Toshinari, McBride, David J., Gillen, Jessica, Wolff, Nicholas C., Morlock, Lorraine, Lotan, Yair, Raj, Ganesh V., Sagalowsky, Arthur, Margulis, Vitaly, Cadeddu, Jeffrey A., Ross, Mark T., Bentley, David R., Kabbani, Wareef, Xie, Xian-Jin, Kapur, Payal, Williams, Noelle S., Brugarolas, James
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3570965/
https://ncbi.nlm.nih.gov/pubmed/22674553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3003643
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak